EUR/USD likely to find a peak near 1.25: UBS
Investing.com -- MaaT Pharma has unveiled its financial results for fiscal year 2024 (FY24), reporting a revenue of €3.2m, a 44% increase from 2023.
This surge in revenue is largely attributed to an increased demand in Expanded Access Program (EAP), supported by the compelling phase 3 (P3) data of MaaT013.
In addition to the FY24 results, the company also disclosed a €13m private placement. While this does not completely alleviate the financial strain, it provides some breathing space until the upcoming key events.
Throughout 2024, MaaT Pharma has laid substantial groundwork, including positive EAP data and a favorable review from the Data Safety Monitoring Board (DSMB). This preparatory work reached a climax in January 2025 with a remarkable ARES P3 readout for MaaT013 in the treatment of acute graft versus host disease (aGvHD).
The company is now focusing on its Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA), which is expected in June 2025.
MaaT033 also bolstered its long-term stance in 2024, showing clean safety data in two separate trials, PHOEBUS in allogeneic hematopoietic stem cell transplantation (allo-HSCT), and IASO in Amyotrophic Lateral Sclerosis (ALS).
The year 2024 proved to be significant for MaaT Pharma, not only validating its platform in aGvHD but also demonstrating safety across different indications. The company looks forward to accelerating data maturity in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.